{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:05:45Z","timestamp":1747181145806,"version":"3.40.5"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,16]]},"abstract":"<jats:p>In patients with acute onset dilated cardiomyopathy (DCM) an improvement of left ventricular ejection fraction (LVEF) can occur as an effect of complex therapy. The aim of the study was to evaluate a pharmacotherapeutic impact on LVEF recovery in newly diagnosed DCM heart failure (HF) patients. A total of 2436 patients hospitalized due to acute decompensated HF were retrospectively analyzed. Finally, 24 patients with newly diagnosed DCM (51.4\u2005\u00b1\u200516.3 years, New York Heart Association 2.3\u2005\u00b1\u20050.7, LVEF 25\u2005\u00b1\u200510%) were observed (13.4\u2005\u00b1\u200516.0 months) in terms of the result of complex therapy. Patients were divided according to LVEF improvement on follow-up echocardiography: \u201crecovery group\u201d (LVEF improvement\u2005&gt;\u20055%; n\u2005=\u200513) and \u201cnonrecovery group\u201d (\u2206LVEF\u2005\u2264\u20055%; n\u2005=\u200511). Evaluation of baseline parameters showed lower LVEF (19\u2005\u00b1\u20056 vs 31\u2005\u00b1\u200510%; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.0048) and lower incidence of arterial hypertension (27% vs 73%; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.043) in \u201crecovery\u201d group. After follow-up period LVEF was similar in both groups; however, significant LVEF improvement was demonstrated only in the \u201crecovery group\u201d (19\u2005\u00b1\u20056% to 34\u2005\u00b1\u20058%; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001). Only the \u201crecovery group\u201d showed significant HF symptoms reduction (New York Heart Association class: 2.5\u2005\u00b1\u20050.7 to 1.6\u2005\u00b1\u20050.6; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.003). The \u201crecovery group\u201d had prescribed higher doses of loop diuretic (equivalent dose of furosemidum: 80\u2005\u00b1\u200538\u2009mg vs 43\u2005\u00b1\u200524\u2009mg; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.025). Despite optimal therapy, significant LVEF improvement is observed only in the half of the patients with newly diagnosed DCM with HF with reduced EF. Prescription of higher doses of loop diuretics may have positive effect on the reduction of symptoms in newly diagnosed DCM HF patients. Lack of other risk factors such as arterial hypertension may increase the chance of LVEF recovery.<\/jats:p>","DOI":"10.1097\/md.0000000000033761","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T18:02:03Z","timestamp":1686938523000},"page":"e33761","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of the pharmacotherapeutic impact on contractility recovery in patients with newly diagnosed, acute onset dilated cardiomyopathy"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0906-0857","authenticated-orcid":false,"given":"Michal","family":"Orszulak","sequence":"first","affiliation":[{"name":"First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sugarmaa","family":"Baasansuren","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Balwierz","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi\u0142osz","family":"Cempa","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Halfar","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneta","family":"Zimol\u0105g","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaudia","family":"M\u0119cka","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej T.","family":"Wybraniec","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Mizia-Stec","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/heart.84.1.106","article-title":"Cardiomyopathy. Diagnosis and management of dilated cardiomyopathy.","volume":"84","author":"Elliott","year":"2000","journal-title":"Heart"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1016\/j.jacc.2016.03.590","article-title":"The diagnosis and evaluation of dilated cardiomyopathy.","volume":"67","author":"Japp","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R3-20250504","first-page":"00050","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure [published online ahead of print, 2021 Mar 1].","volume":"S1071-9164","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","article-title":"Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography.","volume":"32","author":"Mitchell","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"727727","DOI":"10.1002\/ejhf.591","article-title":"Erratum to \u201cTraditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency\u201d [Eur J Heart Fail 2016;18:482-489].","volume":"18","author":"Anker","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ejhf.1799","article-title":"Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF.","volume":"23","author":"Mordi","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"e0231076","DOI":"10.1371\/journal.pone.0231076","article-title":"Patient-Reported compliance in older age patients with chronic heart failure.","volume":"15","author":"Jankowska-Pola\u0144ska","year":"2020","journal-title":"PLoS One"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"7262","DOI":"10.4238\/2014.September.5.11","article-title":"Torasemide reduces dilated cardiomyopathy, complication of arrhythmia, and progression to heart failure.","volume":"13","author":"Han","year":"2014","journal-title":"Genet Mol Res"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejphar.2007.11.034","article-title":"Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy.","volume":"581","author":"Veeraveedu","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"e122831","DOI":"10.1111\/1755-5922.12283","article-title":"Comparative evaluation of torasemide and spironolactone on adverse cardiac remodeling in a rat model of dilated cardiomyopathy.","volume":"35","author":"Arumugam","year":"2017","journal-title":"Cardiovasc Ther"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1440-1681.2009.05184.x","article-title":"Dilated cardiomyopathy with hypertension: prevalence and response to high-dose \u03b21-adrenoceptor antagonist therapy.","volume":"36","author":"Zheng","year":"2009","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"9463872","DOI":"10.1155\/2019\/9463872","article-title":"Utilization and dose optimization of angiotensin-converting enzyme inhibitors among heart failure patients in southwest ethiopia.","volume":"2019","author":"Niriayo","year":"2019","journal-title":"Biomed Res Int"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e0212907e0212907","DOI":"10.1371\/journal.pone.0212907","article-title":"Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: systematic review and meta-analysis.","volume":"14","author":"Turgeon","year":"2019","journal-title":"PLoS One"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1536\/ihj.20-671","article-title":"The use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers is associated with the recovered ejection fraction in patients with dilated cardiomyopathy.","volume":"62","author":"Enzan","year":"2021","journal-title":"Int Heart J"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jacc.2010.11.030","article-title":"Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment.","volume":"57","author":"Merlo","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ehf2.13161","article-title":"Modification of ventriculo-arterial coupling by spironolactone in nonischemic dilated cardiomyopathy.","volume":"8","author":"Lawson","year":"2021","journal-title":"ESC Heart Fail"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1006\/jmcc.1994.1098","article-title":"Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone.","volume":"26","author":"Brilla","year":"1994","journal-title":"J Mol Cell Cardiol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1248\/bpb.b212023","article-title":"Dilated cardiomyopathy: a disease of the myocardium.","volume":"36","author":"Sanbe","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"R24-20250504","first-page":"138","article-title":"Therapie der dilatativen Kardiomyopathie mit digitalis, diuretika und vasodilatatoren [Therapy of dilated cardiomyopathy with digitalis, diuretics and vasodilators].","volume":"10","author":"Liebau","year":"1985","journal-title":"Herz"},{"key":"R25-20250504","first-page":"164","article-title":"Sympathische aktivit\u00e4t bei patienten mit herzinsuffizienz auf dem boden einer idiopathischen dilatativen kardiomyopathie: einfluss von ace-hemmern und anderen vasodilatatoren [Sympathetic activity in patients with heart failure due to idiopathic dilated cardiomyopathy: effect of ace inhibitors and other vasodilators].","volume":"15","author":"Langes","year":"1990","journal-title":"Herz"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/ehf2.13453","article-title":"Effect of aggressive diuresis in acute heart failure with reduced and preserved ejection fraction.","volume":"8","author":"He","year":"2021","journal-title":"ESC Heart Fail"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1440014400","DOI":"10.3390\/ijerph192114400","article-title":"Heart failure with improved ejection fraction: insight into the variable nature of left ventricular systolic function.","volume":"19","author":"Wybraniec","year":"2022","journal-title":"Int J Environ Res Public Health"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033761","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:09:06Z","timestamp":1746320946000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":26,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033761","relation":{},"ISSN":["0025-7974"],"issn-type":[{"type":"print","value":"0025-7974"}],"subject":[],"published":{"date-parts":[[2023,6,16]]}}}